Anti-Human Epidermal Growth Factor Receptor (EGFR) (Clone F4) – Purified
Anti-Human Epidermal Growth Factor Receptor (EGFR) (Clone F4) – Purified
Product No.: E102
- -
- -
Clone F4 Target EGFR Formats AvailableView All Product Type Monoclonal Antibody Alternate Names ErbB-1, HER1 Isotype IgG1 Applications IHC FFPE , IP , WB |
Data
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Immunogen A peptide (residues 985 to 996 of human EGFR) coupled to keyhole limpet hemocyanin. Product Concentration 0.5 mg/ml Formulation This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This purified antibody is stable when stored at 2-8°C. Do not freeze. Country of Origin USA Shipping Next Day Ambient RRIDAB_2829968 Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Anti-EGFR (clone F4) recognizes the internal domain with an epitope between amino acids 985-996 from the complete EGF receptor sequence of 1206 amino acids. It is thus about 200 residues from the C-terminus but just outside the region of sequence homology shared by the src oncogene family.4 Background EGFR (epidermal growth factor receptor) exists on the cell surface and is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor α (TGFα). Upon activation by its growth factor ligands, EGFR undergoes a transition from an inactive monomeric form to an active homodimer - although there is some evidence that preformed inactive dimers may also exist before ligand binding. In addition to forming homodimers after ligand binding, EGFR may pair with another member of the ErbB receptor family, such as ErbB2/Her2/neu, to create an activated heterodimer. There is also evidence to suggest that clusters of activated EGFRs form, although it remains unclear whether this clustering is important for activation itself or occurs subsequent to activation of individual dimers. Over expression of the EGF-receptor is a hallmark of squamous cell carcinomas. PubMed Research Area Cancer . Cell Biology . Immunology . Innate Immunity . Neuroinflammation . Neuroscience References & Citations1. Berger, S. M. et al. (1987) J. of Pathology 152:297
2. Downward, J. et al. (1984) Nature 311:483
3. Gullick, W. J. et al. (1985) EMBO J. 4:2869
4. Gullick, W. J. et al. (1986) Cancer Research 46:285
5. Gullick, W. J. et al. (1991) Br. Med. Bulletin 47:87 Technical ProtocolsCertificate of Analysis |
Formats Available
- -
- -
![Disclaimer Alert Disclaimer Alert](https://d2qwdhcng2065c.cloudfront.net/wp-content/themes/Avada-Child-Theme/disclaimer.jpg)